# Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

> **NCT01356849** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 149 (actual)

## Conditions studied

- Chronic Kidney Disease
- Diabetic Nephropathy

## Interventions

- **DRUG:** Atrasentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01356849
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2013-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356849, "Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01356849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*